Figure 1.

Investigator Global Assessment‐rated severity (a) and reasons for categorization (b) of the Cyclo and immunomodulatory agent (IMM) subpopulations. *Numbers of patients for each reason add up to more than the group number, as some patients were characterized by multiple reasons. Cyclo, participants with inadequate efficacy for or contraindications or intolerance to cyclosporine; IMM, participants with inadequate efficacy for or contraindications or intolerance to any systemic immunomodulatory agent (including Cyclo participants).